Skye Bioscience, Inc. Common Stock (SKYE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has a cash flow conversion efficiency ratio of -0.950x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.56 Million) by net assets ($9.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SKYE net asset quality index to measure how much of total assets are equity-financed.
Skye Bioscience, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Skye Bioscience, Inc. Common Stock (SKYE) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Skye Bioscience, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beam Global
NASDAQ:BEEM
|
-0.175x |
|
Han Express
KO:014130
|
0.053x |
|
Everbright Digital Holding Limited Ordinary Shares
NASDAQ:EDHL
|
N/A |
|
Gotland Rederi AB Series B
ST:GOTL-B
|
-0.015x |
|
Fabrity Holding S.A.
WAR:FAB
|
0.028x |
|
Next Entertainment World Co. Ltd
KQ:160550
|
0.005x |
|
Tainwala Chemical and Plastic (I) Limited
NSE:TAINWALCHM
|
-0.028x |
|
LendingClub Corp
NYSE:LC
|
-0.406x |
Annual Cash Flow Conversion Efficiency for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual cash flow conversion efficiency of Skye Bioscience, Inc. Common Stock from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Skye Bioscience, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.02 Million | $-43.06 Million | -2.151x | -480.73% |
| 2024-12-31 | $68.15 Million | $-25.24 Million | -0.370x | -105.66% |
| 2023-12-31 | $-2.13 Million | $-13.95 Million | 6.545x | +54.48% |
| 2022-12-31 | $-3.01 Million | $-12.74 Million | 4.237x | +483.70% |
| 2021-12-31 | $5.86 Million | $-6.47 Million | -1.104x | +91.78% |
| 2020-12-31 | $450.79K | $-6.05 Million | -13.430x | -22.11% |
| 2019-12-31 | $548.06K | $-6.03 Million | -10.999x | -4440.97% |
| 2018-12-31 | $-15.56 Million | $-3.94 Million | 0.253x | -93.85% |
| 2017-12-31 | $-800.08K | $-3.30 Million | 4.122x | +68.34% |
| 2016-12-31 | $-1.45 Million | $-3.55 Million | 2.449x | +130.94% |
| 2015-12-31 | $471.00K | $-3.73 Million | -7.915x | -304.53% |
| 2014-12-31 | $-453.55K | $-1.76 Million | 3.870x | +873.40% |
| 2013-12-31 | $-36.46K | $-14.49K | 0.398x | +695.12% |
| 2012-12-31 | $38.56K | $1.93K | 0.050x | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company wa… Read more